Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.
Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.
复制标题
生物人工肝治疗严重肝衰竭的临床经验。
DOI：
10.1097/00000658-199705000-00005
复制
发表时间：
1997
影响因子：
9
通讯作者：
Demetriou,AA
中科院分区：
文献类型：
--
作者：
Watanabe,FD;Mullon,CJ;Hewitt,WR;Arkadopoulos,N;Kahaku,E;Eguchi,S;Khalili,T;Arnaout,W;Shackleton,CR;Rozga,J;Solomon,B;Demetriou,AA
目的本研究的目的是开发一种生物人工肝（BAL）治疗严重肝衰竭患者，直到他们可以移植或自发恢复。摘要背景资料严重急性肝衰竭与高死亡率。肝移植已成为对标准治疗无反应的患者的有效治疗方法。然而，由于供体器官短缺和迫切需要移植，许多患者死亡之前，他们可以移植和其他人不移植后生存，主要是因为颅内高压。第1组（n= 18）为暴发性肝功能衰竭（FHF）患者，第2组（n= 3）为移植肝原发性无功能（PNF）患者，第3组（n= 10）为慢性肝病急性加重患者。第1组和第2组的患者在他们进入研究的时候是移植的候选人，而第3组的患者则没有。结果在第1组中，16例患者”桥接”成功移植，1例患者桥接恢复没有移植，1例患者死亡，因为伴随严重胰腺炎。第2组所有患者均成功桥接至再次移植。在第3组中，两名患者的支持恢复和成功的移植在以后的日期;其他8例患者，虽然暂时支持与BAL，后来死亡，因为他们不是候选人transplantation.Conclusions作者的临床经验与BAL取得了令人鼓舞的结果。一项随机、对照、前瞻性试验（II-III期）正在启动，以确定该系统的有效性。
Objective The purpose of this study was to develop a bioartificial liver (BAL) to treat patients with severe liver failure until they can be either transplanted or recover spontaneously.Summary Background Data Severe acute liver failure is associated with high mortality. Liver transplantation has emerged as an effective therapy for patients who did not respond to standard management. However, because of the donor organ shortage and urgent need for transplantation, many patients die before they can be transplanted and others do not survive after transplantation, primarily because of intracranial hypertension.Methods Three groups of patients with severe acute liver failure were treated with the BAL. In group 1 (n= 18) were patients with fulminant hepatic failure (FHF), in group 2 (n= 3) were patients with primary nonfunction (PNF) of a transplanted liver, and in group 3 (n= 10) were patients with acute exacerbation of chronic liver disease. Patients in groups 1 and 2 were candidates for transplantation at the time they entered the study, whereas patients in group 3 were not.Results In group 1, 16 patients were" bridged" successfully to transplantation, 1 patient was bridged to recovery without a transplant, and 1 patient died because of concomitant severe pancreatitis. In group 2, all patients were bridged successfully to retransplantation. In group 3, two patients were supported to recovery and successful transplants at later dates; the other eight patients, although supported temporarily with the BAL, later died because they were not candidates for transplantation.Conclusions The authors' clinical experience with the BAL has yielded encouraging results. A randomized, controlled, prospective trial (phase II-III) is being initiated to determine the efficacy of the system.
登录
查看更多内容
全血冲洗和交换。
影响因子：
3
作者：
G. Cooper;K. Karlson;G. H. Clowes;H. Martin;H. Randall
通讯作者：
H. Randall
DOI：
10.1016/s0140-6736(77)90001-0
发表时间：
1977
期刊：
The Lancet
影响因子：
--
作者：
D. Silk;P. Trewby;R. Chase;P. Mellon;M. A. Hanid;M. Davies;P. Langley;P. Wheeler;Roger Williams
通讯作者：
Roger Williams
影响因子：
1.7
作者：
BIHARI, D;HUGHES, RD;WILLIAMS, R
通讯作者：
WILLIAMS, R
自动化肝细胞处理促进猪肝细胞的大规模分离和纯化
影响因子：
4.2
作者：
E. Morsiani;J. Rozga;Henri C. Scott;L. Lebow;A. Moscioni;L. Kong;M. McGrath;A. Demetriou
通讯作者：
A. Demetriou
影响因子：
1.5
作者：
F. Watanabe;A. Demetriou
通讯作者：
A. Demetriou